Latest Breaking News On - First pediatric cardiomyopathy gene therapy trial - Page 1 : comparemela.com

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJessie yeungKevin giordanoGaurav shahHeart failure society of americaYork heart associationCorporate communicationsYork health associationRocket pharmaceuticals incNew york health associationDisease trialHeart failure societyAnnual scientific meetingDanon diseaseChief executive officerNew york heart association

Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort — — Company to webcast. | September 16, 2022

United statesJoseph rossanoHeart failure society of americaGaylord national harbor convention centerMeeting of the american society geneRocket pharmaceuticals incRocket pharmaceuticalsDisease trialHeart failure societyAnnual scientific meetingAnnual meetingAmerican societyCell therapySafety profileFirst pediatric cardiomyopathy gene therapy trialDanon disease